देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
THROMBIN (HUMAN); COLLAGEN; FIBRINOGEN (HUMAN)
CORZA MEDICAL GMBH
B02BC30
COMBINATIONS
2UNIT; 2.1MG; 5.5MG
PATCH
THROMBIN (HUMAN) 2UNIT; COLLAGEN 2.1MG; FIBRINOGEN (HUMAN) 5.5MG
TOPICAL
2
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0356730001; AHFS:
APPROVED
2022-02-25
_TachoSil_ _®_ _, Absorbable fibrin sealant patch _ _Page 1 of 18_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION TACHOSIL® Human fibrinogen, h uman thrombin and collagen sponge, absorbable fibrin sealant patch Patch, 5.5 mg Human Fibrinogen, 2.0 IU Human Thrombin and 2.1 mg Collagen Sponge per cm 2 , Topical Hemostatic Agent Corza Medical GmbH 21 Speditionsstraße Düsseldorf, Germany 40221 Date of Initial Authorization: March 12, 2015 Date of Revision: February 25, 2022 Submission Control Number: 256367 _TachoSil_ _®_ _, Absorbable fibrin sealant patch _ _Page 1 of 33_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS .............................................................................................................. 2 SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. ... 2 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics (<18 years of age) .............................................................................. 4 1.2 Geriatrics (> 65 years of age) .............................................................................. 4 2 CONTRAINDICATIONS ................................................................................................... 4 4 DOSAGE AND ADMINISTRATION................................................................................. 4 4.1 Dosing Considerations ....................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment..................................................... 4 4.4 Administration................................................................................................... 5 4.5 Missed Dose ...................................................................................................... 5 5 OVERDOSAGE ....................................................... पूरा दस्तावेज़ पढ़ें